Trillium Asset Management LLC boosted its stake in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) by 1.5% during the second quarter, Holdings Channel reports. The firm owned 65,295 shares of the biotechnology company’s stock after buying an additional 955 shares during the period. Trillium Asset Management LLC’s holdings in Five Prime Therapeutics were worth $1,966,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Trexquant Investment LP bought a new position in shares of Five Prime Therapeutics during the first quarter worth about $784,000. Arxis Securities LLC bought a new position in shares of Five Prime Therapeutics during the first quarter worth about $267,000. Virginia Retirement Systems ET AL raised its position in shares of Five Prime Therapeutics by 50.9% in the first quarter. Virginia Retirement Systems ET AL now owns 40,300 shares of the biotechnology company’s stock worth $1,457,000 after buying an additional 13,600 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Five Prime Therapeutics by 7.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,030 shares of the biotechnology company’s stock worth $724,000 after buying an additional 1,302 shares during the last quarter. Finally, Pictet Asset Management Ltd. raised its position in shares of Five Prime Therapeutics by 38.1% in the first quarter. Pictet Asset Management Ltd. now owns 243,675 shares of the biotechnology company’s stock worth $8,809,000 after buying an additional 67,163 shares during the last quarter. Hedge funds and other institutional investors own 84.36% of the company’s stock.

Shares of Five Prime Therapeutics, Inc. (FPRX) opened at 27.76 on Wednesday. The stock has a 50 day moving average of $29.24 and a 200 day moving average of $34.38. Five Prime Therapeutics, Inc. has a 12-month low of $25.97 and a 12-month high of $60.98. The stock’s market capitalization is $776.86 million.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by $0.43. Five Prime Therapeutics had a negative return on equity of 31.78% and a negative net margin of 356.39%. The company had revenue of $7.80 million for the quarter, compared to analyst estimates of $8.32 million. During the same period in the previous year, the business posted ($0.49) EPS. The firm’s revenue for the quarter was down 16.1% compared to the same quarter last year. Equities research analysts anticipate that Five Prime Therapeutics, Inc. will post ($5.05) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/five-prime-therapeutics-inc-fprx-stake-raised-by-trillium-asset-management-llc/1494458.html.

FPRX has been the topic of a number of recent analyst reports. ValuEngine upgraded shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Jefferies Group LLC restated a “buy” rating and set a $55.00 price target on shares of Five Prime Therapeutics in a research note on Friday, May 5th. Zacks Investment Research upgraded shares of Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $39.00 price target on the stock in a research note on Wednesday, April 26th. Finally, BidaskClub lowered shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $60.80.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics, Inc. (NASDAQ:FPRX).

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.